About VGXI
VGXI is a company based in The Woodlands (United States) founded in 1997. VGXI operates in a competitive market with competitors including Metabolon, Maze Therapeutics, Seer, Alector and Scailyte, among others.
- Headquarter The Woodlands, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of VGXI
Unlock access to complete
Funding Insights of VGXI
- Total Funding Total Funding
- Total Rounds 1
- Last Round Last Round
- First Round First Round
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2020 | Amount | Grant - VGXI | Valuation |
investors |
Investors in VGXI
Investments & Acquisitions by VGXI
Financial Statements - VGXI
Vgxi Comparisons
Competitors of VGXI
VGXI operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Metabolon, Maze Therapeutics, Seer, Alector and Scailyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Solutions for biomarker discovery and diagnostic testing are provided.
|
|
| domain | founded_year | HQ Location |
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
|
|
| domain | founded_year | HQ Location |
Proteomics platform developed for early cancer and neurological disease detection.
|
|
| domain | founded_year | HQ Location |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
|
|
| domain | founded_year | HQ Location |
Single-cell data is analyzed via AI for biomarker discovery.
|
|
| domain | founded_year | HQ Location |
NeoPhore is focused on cancer neoantigen evolution therapies.
|
Frequently Asked Questions about VGXI
VGXI was founded in 1997 and raised its 1st funding round 23 years after it was founded.
VGXI is headquartered in The Woodlands, United States. It is registered at The Woodlands, Texas, United States.
Young K Park is the current CEO of VGXI.
VGXI was established in 1997 as a contract manufacturing organization in the biotechnology sector, based in The Woodlands, United States. Services encompass cGMP plasmid DNA production for clinical and commercial applications, highly documented plasmids for viral and toxicological studies, and high-purity preparations for preclinical research. As a subsidiary of GeneOne Life Science, operations support DNA vaccine and gene therapy development.
VGXI's top competitors include Alector, Maze Therapeutics and Metabolon.
VGXI has 1 investor. Key investors include CEPI.